Orris

Sibelium mode of action

Reading File
Finding Sources
Searching the Web

Sibelium flunarizine mechanism of action

Sibelium (Flunarizine) - Mechanism of Action

Sibelium is the brand name for flunarizine, a diphenylmethylpiperazine derivative classified as a calcium channel blocker, used mainly for migraine prophylaxis and vertigo (vestibular disorders).

Primary mechanism: Calcium channel blockade

  • Flunarizine is a selective calcium entry blocker that inhibits the influx of extracellular calcium through voltage-dependent calcium channels in neurons and vascular smooth muscle, acting on both T-type and L-type channels, though its affinity for these channels is lower than classic dihydropyridines, verapamil, or diltiazem (Katzung's Basic and Clinical Pharmacology, 16th Ed).
  • By reducing intracellular calcium, it decreases neuronal excitability and inhibits smooth muscle contraction, causing dilation of cerebral/systemic arteries and reducing vasospasm.
  • Some evidence suggests part of its effect may not be from direct channel blockade but from an intracellular action, such as antagonizing calmodulin (a calcium-binding regulatory protein), which would explain its relatively weak direct calcium-channel affinity relative to its clinical potency.

Relevance to migraine prophylaxis

  • Reduces the frequency and severity of migraine attacks, believed to work through:
    • Blocking calcium-dependent nitric oxide release at cerebral nerve terminals, which normally contributes to neurogenic vasodilation
    • Raising the threshold for cortical spreading depression, the phenomenon thought to underlie migraine aura
    • Stabilizing neuronal membranes and reducing excessive excitability linked to migraine pathophysiology

Additional (non-calcium-channel) actions

Flunarizine has several secondary pharmacologic effects that contribute to both efficacy and side-effect profile:
  • Antihistaminic activity (H1 receptor antagonism)
  • Dopamine D2 receptor antagonism - this is clinically important because it explains why flunarizine (like the related drug cinnarizine) can cause drug-induced parkinsonism and other extrapyramidal symptoms with chronic use (Bradley and Daroff's Neurology in Clinical Practice; Goldman-Cecil Medicine)
  • Mild serotonin receptor blocking activity

Use in vertigo

The same calcium-channel blocking action reduces excitability of vestibular sensory cells and stabilizes labyrinthine function, which is why it's also used for vertigo/tinnitus (Scott-Brown's Otorhinolaryngology).

Clinical caution

Because of its dopamine-blocking activity, flunarizine is contraindicated or used cautiously in patients with Parkinson's disease, other extrapyramidal disorders, or depression, since it can induce or worsen parkinsonism and depressive symptoms. It is not available in the United States, though it's used in Europe, Latin America, and Asia.
A note on evidence currency: a 2023 European Headache Federation meta-analysis (Springer, "critical re-appraisal... part 2: flunarizine") supports these proposed mechanisms (NO release inhibition, raised cortical spreading depression threshold, D2 antagonism) but the exact molecular basis for its clinical efficacy in migraine is still not fully settled - some effects may be indirect rather than purely due to calcium channel blockade.
This is a shared conversation. Sign in to Orris to start your own chat.